Baseline Characteristics and Maintenance Therapy Choice on Symptom Control, Reliever Use, Exacerbation Risk in Moderate–Severe Asthma: A Clinical Modelling and Simulation Study-Reference-Cited by-同舟云学术

Baseline Characteristics and Maintenance Therapy Choice on Symptom Control, Reliever Use, Exacerbation Risk in Moderate–Severe Asthma: A Clinical Modelling and Simulation Study

Published:2024-09-06 Issue: Volume: Page:
ISSN:0741-238X
Container-title:Advances in Therapy
language:en
Short-container-title:Adv Ther

Author:

Paggiaro Pierluigi,Garcia Gabriel,Roche Nicolas,Verma Manish,Plank Maximilian,Oosterholt Sean,Duong Janna K.,Majumdar Anurita,Della Pasqua Oscar^ORCID

Funder

GlaxoSmithKline

Publisher

Springer Science and Business Media LLC

Link

https://link.springer.com/content/pdf/10.1007/s12325-024-02962-2.pdf

Reference52 articles.

1. 2023 GINA Report, Global Strategy for Asthma Management and Prevention. Available at: https://ginasthma.org/2023-gina-main-report/. Accessed 16/10/2023.

2. Oosterholt S, Pavord ID, Brusselle G, et al. Modelling Asthma TrEatment Responses (MASTER): effect of individual patient characteristics on the risk of exacerbation in moderate or severe asthma: a time-to-event analysis of randomized clinical trials. Br J Clin Pharmacol. 2023. https://doi.org/10.1111/bcp.15801.

3. van Dijkman SC, Yorgancıoğlu A, Pavord I, et al. Effect of individual patient characteristics and treatment choices on reliever medication use in moderate-severe asthma: a Poisson analysis of randomised clinical trials. Adv Ther. 2024;41:1201–25.

4. Singh D, Oosterholt S, Pavord I, et al. Understanding the clinical implications of individual patient characteristics and treatment choice on the risk of exacerbation in asthma patients with moderate–severe symptoms. Adv Ther. 2023;40:4606–25.

5. Juniper EF, O’Byrne PM, Guyatt GH, Ferrie PJ, King DR. Development and validation of a questionnaire to measure asthma control. Eur Respir J. 1999;14:902–7.